Apr 1, 2019 9:20 am EDT Acasti Pharma Announces Publication of CaPre Bioavailability Study in Leading Peer-Reviewed Journal
Mar 26, 2019 8:30 am EDT Acasti Pharma to Present at the 2019 Spring Investor Summit in New York City on April 2nd
Mar 13, 2019 8:30 am EDT Acasti Pharma to Present at the Oppenheimer 29th Annual Healthcare Conference on March 19th
Jan 9, 2019 8:00 am EST Acasti Pharma Awarded Broad Composition-of-Matter and Method of Use Patents by the European Patent Office
Dec 31, 2018 8:00 am EST Acasti Pharma Announces TRILOGY Phase 3 Trials of CaPre® in Patients with Severe Hypertriglyceridemia Has Now Exceeded 65% Randomization, and More Than 100 Patients (>20%) Have Completed Their 6 Month Treatment Plan
Dec 20, 2018 8:00 am EST Acasti Pharma Achieves Planned Enrollment Targets for TRILOGY Phase 3 Trials of CaPre® in Patients with Severe Hypertriglyceridemia